Narrow therapeutic range drugs
Maryland removes six narrow therapeutic range drugs from its formulary of equivalent drug products, effective Dec. 27. The products, all in solid oral dosage forms, are carbamazepine, phenytoin sodium extended, primidone, valproic acid, theophylline extended release and warfarin sodium.
You may also be interested in...
BVMed says the EU and the UK should set up a system of mutual recognition of medical device regulation to kick in when the UK’s EU exit transition period ends on 31 December.
HER3 may be a new target for anticancer antibody-drug conjugates; clinical investigators posted promising early stage clinical results with Daiichi Sankyo’s HER3 targeting antibody-drug conjugate, patritumab deruxtecan, at the recent ESMO virtual meeting.
After a slow start marked by product withdrawals and toxicity, recent deal-making activity has brought antibody-drug conjugates back from obscurity. But what has changed?